Project Grant R01CA300241
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $610K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78229, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded a $404,972 Project Grant to The University of Texas Health Science Center at San Antonio under the Cancer Biology Research program (CFDA 93.396) for a two-year project period beginning August 1, 2025 and concluding July 31, 2027. This award supports fundamental research investigating ribosomal ribonucleic acid (rRNA) modification, ribosome composition, and specialized translation mechanisms in glioblastoma, the most common and...
- Federal Project Grant Award Summary The University of Texas Health Science Center at Houston received a $393,872 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025 through July 31, 2027. The award supports research and development of therapeutic antibody-drug conjugates (ADCs) targeting leucine-rich repeat containing G protein-coupled receptor 5 (LGR5) and the receptor tyrosine kinase MET to overcome tumor...
- Federal Project Grant Award Summary The National Cancer Institute awarded $593,338 to The University of Texas Health Science Center at San Antonio under the Cancer Treatment Research program (CFDA 93.395) on March 25, 2026, for the development of first-in-class AP2 associated kinase 1 (AAK1) proteolysis-targeting chimeras (PROTACs) targeting ovarian cancer treatment resistance. The project, extending through February 28, 2031, addresses a critical clinical challenge in ovarian cancer therapy:...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Project Grant Award Summary The National Cancer Institute awarded The University of Texas Health Science Center at Tyler a $219,024 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2025, through June 30, 2027. The grant supports research on CSP7 (Caveolin-1 Scaffolding Domain 7-mer Peptide), a therapeutic agent designed to inhibit radiation-induced lung toxicity in cancer patients undergoing radiotherapy. The research addresses a significant...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $616,715 to The University of Texas MD Anderson Cancer Center, with an award date of August 11, 2025 and completion date of July 31, 2030. This award supports research under the Cancer Treatment Research program (CFDA 93.395), which develops and evaluates improved methods of cancer treatment through fundamental and applied laboratory and clinical research. The funded research centers on the...
- Federal Project Grant Award Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded a $164,000 Project Grant to The University of Texas MD Anderson Cancer Center, effective September 1, 2025, through August 31, 2027. This award supports research investigating the clonal determinants of platinum/PARP inhibitor (PARPi) cross-resistance in high-grade serous ovarian cancer (HGSOC). The research utilizes a novel somatic mosaic genetically-engineered mouse model...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $163,500 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on July 2, 2025, with completion scheduled for June 30, 2027. This award supports research aimed at developing targeted therapeutic approaches for E-cadherin-negative diffuse-type gastric adenocarcinoma (DGAC), an aggressive cancer subtype with increasing incidence rates and poor...
- Federal Grant Award Summary The University of Texas at Austin received a $668,878 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on April 3, 2026, with a completion date of March 31, 2031. This award supports the development of a novel antibody-drug conjugate (ADC) therapeutic platform targeting CD44 variant 9 (CD44V9) for advanced and treatment-resistant breast cancer. The research aims to overcome current limitations in...
- Federal Grant Award Summary The University of North Texas received a $148,500 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), with an award date of September 5, 2025, and completion date of August 31, 2027. The research project evaluates the role of extracellular vesicles (EVs) in tumor microenvironment modulation, specifically investigating how tumor-derived EVs contribute to immunosuppression in non-small cell lung cancer...